Intervention

Hydroxyurea

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 21 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials21

Recruiting2

Common conditions15

Lead sponsors shown12

Clinical trials

21 shown

Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailureNCT03500731 · 2018-04-19

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTNCT01962415 · 2014-02-04

Hydroxyurea in Pulmonary Arterial HypertensionNCT01950585 · 2013-09-06

Hydroxyurea in Primary Progressive Multiple SclerosisNCT01103583 · 2011-07-01

Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary HypertensionNCT00350844 · 2006-07-01

Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral SuppressionNCT00344981 · 2003-06-01

Safety and Effectiveness of a Combination Anti-HIV Drug TreatmentNCT00005018 · 1999-07-01

Combination Drug Treatment of Pediatric HIV InfectionNCT00001818 · 1999-06-01

Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected AdultsNCT00002427 · 1999-05-01

A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV InfectionNCT00002176 · 1997-05-01

A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV InfectionNCT00002177 · 1997-05-01

The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected PatientsNCT00001074

Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug TherapyNCT00008866

A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their BloodNCT00000916

A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as PossibleNCT00000939

Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV InfectionNCT00006339

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV InfectionNCT00000919

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease InhibitorsNCT00002420

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease InhibitorsNCT00002418

A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected PatientsNCT00002230

A Study of MKC-442 in Combination With Other Anti-HIV DrugsNCT00002412

Common conditions

HIV Infections15 Pulmonary Hypertension2 AIDS1 Congenital Bone Marrow Failure Syndromes1 Emphysema or COPD1 Hereditary Anemias1 HIV Infection1 Idiopathic Pulmonary Fibrosis1 Inflammatory Conditions1 Inherited Metabolic Disorders (IMD)1 Juvenile Rheumatoid Arthritis (JRA)1 Multiple Sclerosis1 Primary Immunodeficiency (PID)1 Sickle Cell Disease1 Systemic Juvenile Idiopathic Arthritis (sJIA)1

Leading sponsors

National Institute of Allergy and Infectious Diseases (NIAID) 6 Bristol-Myers Squibb 4 Paul Szabolcs 2 Ann & Robert H Lurie Children's Hospital of Chicago 1 Glaxo Wellcome 1 National Cancer Institute (NCI) 1 National Heart, Lung, and Blood Institute (NHLBI) 1 Northwestern University 1 Research Institute for Genetic and Human Therapy 1 S. Andrea Hospital 1 Triangle Pharmaceuticals 1 University of Maryland, Baltimore 1

Trial status mix

COMPLETED12

TERMINATED4

WITHDRAWN3

RECRUITING2

Phase mix

PHASE211

PHASE15

NA4

PHASE32

EARLY_PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.